Related Experiment Video
Updated: Feb 6, 2026

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
Published on: November 22, 2024
SGLT6 - A pharmacological target for the treatment of obesity?
Tamara Baader-Pagler1, Matthias Eckhardt2, Frank Himmelsbach2
1a CardioMetabolic Diseases Research , Boehringer-Ingelheim Pharma GmbH & Co. KG , Biberach an der Riss , Germany.
Abstract:
Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.
Related Concept Videos
Obesity
Drug Dosing: Obese Patients
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Abuse and Addiction: Pharmacological Phenomena

